It’s been a good week for investors of Pyxis Oncology (NASDAQ:PYXS), to say the least. Over the past 4 sessions Pyxis shares have gained 170%, bringing the year-to-date haul to a mighty 340%. This ...
Pyxis Oncology, Inc. (PYXS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results